ABG

Ally Bridge Group Portfolio holdings

AUM $63M
1-Year Est. Return 199.29%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+199.29%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$63M
AUM Growth
-$56.4M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
28
New
Increased
Reduced
Closed

Top Buys

1
+$7.64M
2
+$6.97M
3
+$6.15M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$3.91M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$3.7M

Top Sells

1
+$15M
2
+$10.2M
3
+$8.17M
4
SLNO icon
Soleno Therapeutics
SLNO
+$7.37M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$7M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$8.98B
$9.44M 14.98%
+70,000
SLNO icon
2
Soleno Therapeutics
SLNO
$2.01B
$7.78M 12.35%
168,029
-134,454
ATAI icon
3
AtaiBeckley Inc
ATAI
$1.26B
$7.01M 11.12%
1,713,105
-573,900
IVA
4
Inventiva
IVA
$1.27B
$6.97M 11.07%
+1,500,000
NERV icon
5
Minerva Neurosciences
NERV
$262M
$6.66M 10.56%
+1,655,500
PRAX icon
6
Praxis Precision Medicines
PRAX
$8.82B
$5.86M 9.3%
+19,882
EWTX icon
7
Edgewise Therapeutics
EWTX
$3.06B
$4.84M 7.68%
+195,000
EPRX
8
Eupraxia Pharmaceuticals
EPRX
$467M
$3M 4.77%
397,895
-517,105
OVID icon
9
Ovid Therapeutics
OVID
$123M
$2.91M 4.62%
+1,785,000
TSHA icon
10
Taysha Gene Therapies
TSHA
$1.22B
$2.51M 3.99%
457,132
-1,440,980
SLDB icon
11
Solid Biosciences
SLDB
$446M
$2.33M 3.7%
413,625
-135,557
WHWK
12
Whitehawk Therapeutics
WHWK
$155M
$1.98M 3.14%
817,939
PMN icon
13
ProMIS Neurosciences
PMN
$58.1M
$1.7M 2.7%
249,339
-1
AMLX icon
14
Amylyx Pharmaceuticals
AMLX
$1.54B
– –
-437,391
ARQT icon
15
Arcutis Biotherapeutics
ARQT
$2.95B
– –
-233,220
ASND icon
16
Ascendis Pharma
ASND
$14.5B
– –
-51,080
AVTX icon
17
Avalo Therapeutics
AVTX
$331M
– –
-178,100
CMPS
18
Compass Pathways
CMPS
$784M
– –
-1,026,382
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$9.88B
– –
-32,662
MLTX icon
20
MoonLake Immunotherapeutics
MLTX
$1.29B
– –
0
DFTX
21
Definium Therapeutics
DFTX
$1.71B
– –
-361,444
MNPR icon
22
Monopar Therapeutics
MNPR
$371M
– –
-64,455
QURE icon
23
uniQure
QURE
$663M
– –
0
REPL icon
24
Replimune Group
REPL
$587M
– –
0
TARS icon
25
Tarsus Pharmaceuticals
TARS
$3.18B
– –
-70,778
1
2